323 related articles for article (PubMed ID: 24053191)
61. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
[TBL] [Abstract][Full Text] [Related]
62. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Lamarca A; McCallum L; Nuttall C; Barriuso J; Backen A; Frizziero M; Leon R; Mansoor W; McNamara MG; Hubner RA; Valle JW
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):723-731. PubMed ID: 29923433
[TBL] [Abstract][Full Text] [Related]
63. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
64. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
65. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
[TBL] [Abstract][Full Text] [Related]
66. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME; Singh S; Strosberg JR; Bubuteishvili-Pacaud L; Degtyarev E; Neary MP; Carnaghi C; Tomasek J; Wolin E; Raderer M; Lahner H; Valle JW; Pommier R; Van Cutsem E; Tesselaar MET; Fave GD; Buzzoni R; Hunger M; Eriksson J; Cella D; Ricci JF; Fazio N; Kulke MH; Yao JC
Lancet Oncol; 2017 Oct; 18(10):1411-1422. PubMed ID: 28838862
[TBL] [Abstract][Full Text] [Related]
67. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
[TBL] [Abstract][Full Text] [Related]
68. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
[TBL] [Abstract][Full Text] [Related]
69. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
[TBL] [Abstract][Full Text] [Related]
70. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
Colao A; Faggiano A; Pivonello R
Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
[TBL] [Abstract][Full Text] [Related]
71. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
[TBL] [Abstract][Full Text] [Related]
72. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
Trials; 2024 Jan; 25(1):58. PubMed ID: 38229199
[TBL] [Abstract][Full Text] [Related]
73. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Caplin ME
Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
[TBL] [Abstract][Full Text] [Related]
74. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
Eriksson B; Renstrup J; Imam H; Oberg K
Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
[TBL] [Abstract][Full Text] [Related]
75. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
Sidéris L; Dubé P; Rinke A
Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
[TBL] [Abstract][Full Text] [Related]
76. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Merola E; Panzuto F; Delle Fave G
Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
[TBL] [Abstract][Full Text] [Related]
77. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
Shimatsu A; Nakamura A; Takahashi Y; Fujio S; Satoh F; Tahara S; Nishioka H; Takano K; Yamashita M; Arima H; Tominaga A; Tateishi S; Matsushita Y
Endocr J; 2021 Jul; 68(7):791-805. PubMed ID: 33692246
[TBL] [Abstract][Full Text] [Related]
78. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
Gardner-Roehnelt NM
Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
[TBL] [Abstract][Full Text] [Related]
79. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]